gms | German Medical Science

63rd Annual Meeting of the German Society of Neurosurgery (DGNC)
Joint Meeting with the Japanese Neurosurgical Society (JNS)

German Society of Neurosurgery (DGNC)

13 - 16 June 2012, Leipzig

PET-CT screening of a family with pheochromocytoma-paraganglioma inherited tumor syndrome

Meeting Abstract

  • B. Knie - Klinik für Neurochirurgie, Vivantes Klinikum im Friedrichshain, Berlin
  • M. Plotkin - Institut für Nuklearmedizin, Vivantes Klinikum im Friedrichshain, Berlin
  • P. Zschieschang - Praxis für Humangenetik, Berlin
  • D. Moskopp - Klinik für Neurochirurgie, Vivantes Klinikum im Friedrichshain, Berlin

Deutsche Gesellschaft für Neurochirurgie. Japanische Gesellschaft für Neurochirurgie. 63. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit der Japanischen Gesellschaft für Neurochirurgie (JNS). Leipzig, 13.-16.06.2012. Düsseldorf: German Medical Science GMS Publishing House; 2012. DocP 080

DOI: 10.3205/12dgnc467, URN: urn:nbn:de:0183-12dgnc4676

Published: June 4, 2012

© 2012 Knie et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.


Outline

Text

Objective: Familial paraganglioma syndromes (hereditary paraganglioma-pheochromocytoma syndromes) are characterized by multiple pheochromocytomas and paragangliomas in an autosomal dominant manner. Early detection through surveillance and removal of tumors (especially carotid body and glomus jugulare tumors) may prevent or minimize complications related to mass effects, lower cranial nerve impairment, catecholamine hypersecretion, and malignant transformation.

The diagnosis of the syndromes in asymptomatic patients can be made by genetic screening. We are currently supervising one of the largest documented families in Germany with genetically determined SDHD gene mutation. Penetrance data would suggest that if screening commenced at 10 years of age, disease would be detected in approximately 96% of patients with an SDHB mutation and in all SDHD mutation carriers. Having confirmed the diagnosis, it is important to localise the tumours and reveal the tumour extent preoperatively. We performed 18F-DOPA PET CT as a new non-invasive and reliable screening method to detect tumors in so far symptomatic gene carriers and enable subsequent surgical therapy.

Methods: PET-CT-Screening of heterozygous genetic carriers (mutation c.317G > T, p.Gly106Val in exon 4 of SDHD gene) of a family with Pheochromocytoma-paraganglioma inherited tumor syndrome.

Results: Our paraganglioma-pheochromocytoma tumor syndrome family has a documented family tree of 35 persons in 5 generations. 6 persons in two generations have genetically determined SDHD mutations. So far we performed 18F-DOPA PET CT in 3 family members and revealed 8 tumors, partially not detected in CT. Two of these persons underwent successful neurosurgical treatment. The third family member is under supervision. Consecutive screening of other family members is planned.

Conclusions: The 18F-DOPA PET CT scan of three so far asymptomatic family members with genetic mutation of SDHD gene revealed paraaortic, adrenal and cervical mass lesions, partially not detected in CT. This enabled early surgical intervention and presumably improved the prognosis of these patients. We therefore assume that PET CT scan is a low-risk and meaningful diagnostic tool for rare genetic disorders such as Pheochromocytoma-paraganglioma inherited tumor syndrome for early detection of mass lesions and consecutively prompt intervention.